Spherium Biomed Shuns Beaten Track To Seek Diamonds In The Rough
Executive Summary
Academia is rich with potential new treatments for patients, but it doesn't always know how to turn those discoveries into good medicines for patients. This is where Spanish biotech firm Spherium Biomed steps in to turn potential into marketable innovation.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.